Leukemia

Protocol #SponsorProtocol Title
NCT01980875


Gilead Sciences
GS-US-312-0118 2013-004551-20
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
NCT01799889

Gilead Sciences
GS-US-339-0102
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies

Significant advances have been made in the past few years in the treatment of chronic leukemia. The most common chronic leukemia, chronic lymphocytic leukemia (CLL), is now treated with targeted immunotherapy, such as Obinutuzumab, usually with chemotherapy. Other oral targeted drugs, such as Ibrutinib and Idelalisib offer chemotherapy-free treatment for resistant CLL. NGOC has participated in trials leading to the approval of each of these drugs and is now conducting trials to improve their efficacy.

Imatinib was a breakthrough treatment in Chronic Myeloid Leukemia (CML), converting a once life-threating malignancy to a disease treatable with a pill. NGOC has been a leading center for enrollment to clinical registries evaluating the effectiveness and safety of the treatment of CML in the community.